MB-106 Generates Responses in BTK Inhibitor–Refractory Waldenström Macroglobulinemia


The CD20-targeted CAR T-cell therapy MB-106 led to responses and was well tolerated in patients with Waldenström macroglobulinemia who were refractory to a BTK inhibitor.

Mazyar Shadman, MD, MPH

Mazyar Shadman, MD, MPH

The CD20-targeted CAR T-cell therapy MB-106 led to responses and was well tolerated in patients with Waldenström macroglobulinemia (WM) who were refractory to a BTK inhibitor, according to data from a single-center phase 1/2 trial (NCT03277729) presented at the 2023 EHA Congress.1,2

Findings showed that evaluable patients (n = 6) experienced an overall response rate of 83%, including a complete response rate of 33%, a very good partial response rate of 16.7%, a partial response rate of 16.7%, and a minor response rate of 16.7%. The lone non-responder had stable disease.

One complete responder remained in remission for 22 months, and their immunoglobulin M (IgM) level decreased rapidly to the normal range following treatment with MB-106 and has remained normal. Notably, no patients received additional anti-WM treatment following MB-106.2

Regarding safety, 5 patients experienced cytokine release syndrome (CRS), including 2 patients who had grade 1 CRS and 3 patients with grade 2 CRS. Additionally, grade 1 immune effector cell–associated neurotoxicity syndrome was reported in 1 patient.

“As we continue to evaluate MB-106 in this single-institution study, we’re encouraged by its potential to become an outpatient treatment option for WM and other B-cell malignancies, including indolent and aggressive non-Hodgkin lymphomas,” lead study author Mazyar Shadman, MD, MPH, an associate professor and physician at Fred Hutch and University of Washington in Seattle, stated in a news release.2 “We have observed ongoing responses to MB-106 with improvements in the quality of response over time, along with a favorable safety profile.”

MB-106 is a fully human, third-generation CAR T-cell therapy featuring 4-1BB and CD28 costimulatory domains.1 In June 2022, the FDA granted an orphan drug designation to the MB-106 for use as a potential therapeutic option in patients with WM.3

The single-center study is enrolling patients with CD20-positive B-cell non-Hodgkin lymphoma. Patients with WM must be previously treated, and those with large B-cell lymphoma need to have received at least 2 lines therapy. Patients with follicular lymphoma or mantle cell lymphoma (MCL) must have received at least 1 prior line of therapy, including a BTK inhibitor for those with MCL. Those with chronic lymphocytic leukemia are required to have prior progression on or intolerance to a BTK inhibitor and/or venetoclax (Venclexta). Patients with other previously treated B-cell non-Hodgkin lymphomas are also permitted to enroll.

Prior treatment with a CD19-targeted CAR T-cell therapy is allowed if a patient’s B cells have recovered to at least 20 cells/µL.

After undergoing lymphodepletion with cyclophosphamide and fludarabine, patients are being treated at escalating doses of MB-106, including 1 x 105 cells/kg, 3.3 x 105 cells/kg, 1 x 106 cells/kg, 3.3 x 106 cells/kg, and 1 x 107 cells/kg. Notably, treatment is being given in an outpatient setting, except for the first patient treated at each dose level.

The primary end point of the study is dose-limiting toxicities. Secondary end points include complete remission rate, progression-free survival, overall survival, and safety.4

The median age of the 6 evaluable patients with WM was 69 years (range, 51-79), and 33% were female. Patients received a median of 7.5 (range, 2-12) prior lines of therapy, and all patients were previously administered a BTK inhibitor, including ibrutinib (Imbruvica; n = 5), acalabrutinib (Calquence; n = 1), and zanubrutinib (Brukinsa; n = 2). All patients experienced disease progression following a BTK inhibitor, and 2 patients (33%) were intolerant to a BTK inhibitor.1

All patients harbored MYD88 L265P mutations and had anemia (<11 g/dL). Additionally, 33% of patients had PET avid lymphadenopathy at baseline. WM risk classifications included high (50%), intermediate (33%), and low (17%). The median baseline IgM level was 2873 mg/dL (range, 547-6481).

Other grade 3/4 adverse effects included leukopenia (83%), neutropenia (100%), lymphopenia (83%), thrombocytopenia (33%), hypotension (33%), hypertension (16%), fatigue (16%), elevated alanine transaminase (16%), and elevated aspartate transaminase (16%).


  1. Shadman M, Yeung C, Redman MW, et al. CD20 CAR-T therapy with MB-106 for BTK inhibitor-refractory Waldenström macroglobulinemia (WM)/lymphoplasmacytic lymphoma (LPK) – single institution study. Presented at: 2023 European Hematology Association Congress; June 8-11, 2023; Frankfurt, Germany. Abstract P1097.
  2. Mustang Bio announces updated results from Waldenstrom macroglobulinemia cohort of ongoing phase 1/2 clinical trial of MB-106, CD20-targeted autologous CAR T therapy. News release. June 12, 2023. Accessed June 26, 2023. https://ir.mustangbio.com/news-events/press-releases/detail/160/mustang-bio-announces-updated-results-from-waldenstrom
  3. Mustang Bio announces orphan drug designation granted to MB-106, a CD20-targeted, autologous CAR T cell therapy for the treatment of Waldenstrom macroglobulinemia. News release. Mustang Bio, Inc. June 22, 2022. Accessed June 26, 2023. https://www.globenewswire.com/news-release/2022/06/22/ 
  4. A phase I/II study to evaluate the safety of cellular immunotherapy using autologous T cells engineered to express a CD20-specific chimeric antigen receptor for patients with relapsed or refractory B cell non-Hodgkin lymphomas. ClinicalTrials.gov. Updated May 6, 2023. Accessed June 26, 2023. https://clinicaltrials.gov/ct2/show/NCT03277729
Related Videos
A panel of 4 experts on chronic graft-versus-host disease
A panel of 4 experts on chronic graft-versus-host disease
Corey Cutler, MD, MPH, and Hana Safah, MD, experts on GvHD
Corey Cutler, MD, MPH, and Hana Safah, MD, experts on GvHD
James K. McCloskey, MD, an expert on leukemia
James K. McCloskey, MD, an expert on leukemia
Amy DeZern, MD, MHS, an expert on MDS
Andrew Brunner, MD, an expert on MDS